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Abstract
The incidence of craniosynostosis is one in every 1,800–2500 births. The gene-environment model proposes that if a genetic
predisposition is coupled with environmental exposures, the effects can be multiplicative resulting in severely abnormal
phenotypes. At present, very little is known about the role of gene-environment interactions in modulating craniosynostosis
phenotypes, but prior evidence suggests a role for endocrine factors. Here we provide a report of the effects of thyroid
hormone exposure on murine calvaria cells. Murine derived calvaria cells were exposed to critical doses of pharmaceutical
thyroxine and analyzed after 3 and 7 days of treatment. Endpoint assays were designed to determine the effects of the
hormone exposure on markers of osteogenesis and included, proliferation assay, quantitative ALP activity assay, targeted
qPCR for mRNA expression of Runx2, Alp, Ocn, and Twist1, genechip array for 28,853 targets, and targeted osteogenic
microarray with qPCR confirmations. Exposure to thyroxine stimulated the cells to express ALP in a dose dependent manner.
There were no patterns of difference observed for proliferation. Targeted RNA expression data confirmed expression
increases for Alp and Ocn at 7 days in culture. The genechip array suggests substantive expression differences for 46 gene
targets and the targeted osteogenesis microarray indicated 23 targets with substantive differences. 11 gene targets were
chosen for qPCR confirmation because of their known association with bone or craniosynostosis (Col2a1, Dmp1, Fgf1, 2, Igf1,
Mmp9, Phex, Tnf, Htra1, Por, and Dcn). We confirmed substantive increases in mRNA for Phex, FGF1, 2, Tnf, Dmp1, Htra1, Por,
Igf1 and Mmp9, and substantive decreases for Dcn. It appears thyroid hormone may exert its effects through increasing
osteogenesis. Targets isolated suggest a possible interaction for those gene products associated with calvarial suture
growth and homeostasis as well as craniosynostosis.
Citation: Cray JJ Jr, Khaksarfard K, Weinberg SM, Elsalanty M, Yu JC (2013) Effects of Thyroxine Exposure on Osteogenesis in Mouse Calvarial Pre-Osteoblasts. PLoS
ONE 8(7): e69067. doi:10.1371/journal.pone.0069067
Editor: Xing-Ming Shi, Georgia Regents University, United States of America
Received April 15, 2013; Accepted June 4, 2013; Published July 23, 2013
Copyright:  2013 Cray et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the American Cleft Palate–Cleft/Craniofacial Anomalies Grant Award, Cleft Palate Foundation, www.cleftline.org. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: JCRAY@gru.edu
Introduction
The thyroid hormones, triiodothyronine (T3) and thyroxine
(T4) are essential for the growth and maintenance of all cells and
organ systems in the body. Recent research has implicated
maternal thyrotoxicosis, hyperthyroidism that results from in-
creased thyroid hormone synthesis and secretion during pregnan-
cy, as a risk factor for craniofacial birth defects. Thyrotoxicosis is
estimated to occur in 1 in every 500 pregnancies and results from
maternal hyperthyroidism accompanying thyroid hormone re-
placement for hypothyroidism [1], maternal Graves Disease
[1,2,3,4] or the presence of thyrotoxic goiter [1,4,5].
The Center for Disease Control National Birth Defects
Prevention Study (CDC NBDPS) has identified maternal thyroid
disease as a risk factor for craniosynostosis with an adjusted odds
ratio of 2.47 [3]. Craniosynostosis is a pathological condition in
which premature fusion of one or more of the calvarial sutures
occurs before the cessation of brain growth. Craniosynostosis itself
has an estimated birth prevalence of 1 case per 1,800–2,500 live
births and involves the overgrowth of bone (synostosis) at the
osteogenic fronts of the developing cranial bones [6]. The suture, a
region of undifferentiated non-bony tissue, normally allows for
prenatal and postnatal brain growth. When craniosynostosis is part
of a syndrome, it is associated with facial, limb, ear, or heart
malformations [7,8], but the disorder most often appears in
isolation (nonsyndromic) [9]. There is significant morbidity due to
craniosynostosis resulting in various secondary effects including
secondary fusion of other sutures, altered cranial base growth, and
midface growth discrepancies [10], elevated intracranial pressure
[6], altered intracranial volume [6,11], and dilation of the
subarachnoid spaces [12]. Such events may result in optic nerve
compression, papilledema, and if left uncorrected, may lead to
optic atrophy, blindness [13], cognitive disabilities, and mental
retardation [14], which pose extensive, costly, and recurrent
clinical and surgical management problems [15,16].
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During fetal development, thyrotropin-releasing hormone
(TRH) and thyroid-stimulating hormone (TSH) are secreted
beginning at 18–20 weeks gestation. These hormones are
produced in the anterior pituitary gland and cause the follicular
cells to take up iodinated thyroglobulin by endocytosis from the
lumen of each thyroid follicle and then submit to lysosomal
digestion. Two products result from the proteolysis, T3 and T4.
T4 is more abundant making up about 90% of circulating
hormone throughout life. Most T4 is converted to T3, a more
rapid and potent hormone which remains at low levels until 30
weeks gestation. The fetus is self-sufficient concerning thyroid
hormone, creating a relatively strong physiological protection
against maternal hypothyroidism, however the hormone does
cross the placental barrier [17,18]. During postnatal growth,
circulating thyroid hormones are known to exert specific effects on
endochondral bone by promoting chondrocyte hypertrophy in the
growth center [18,19,20]. The effects of thyroid hormone on
membrane derived bone (e.g., bone comprising the cranial vault)
have not been well studied.
There have been numerous reports of secondary craniosynos-
tosis associated with hyperthyroidism [1,2,21,22,23], including the
observation that maternal thyrotoxicoses is associated with
development of sagittal and coronal craniosynostosis in the fetus
or infant. In these cases skeletal maturation is advanced, measured
by mineralization and bony thickness, suggesting that membrane
bone may be more responsive to thyroid stimulation than
endochondral bone. In contrast, early onset hypothyroidism
results in widely patent sutures and fontanels suggesting a role
for the homeostasis of thyroid hormone in the maintenance of
patent sutures [5]. However, the biochemical effects of thyroid
hormone on premature cranial suture fusion have yet to be
elucidated, with the exception of identification of Insulin Like
Growth Factors (IGF) presence at the calvarial suture where
thyroid hormone influences the expression positively [24,25]. To
begin to address this deficit in our understanding, we performed a
series of experiments to determine the effects of exogenous thyroid
hormone exposure on cells derived from murine calvaria. The
MC3T3-E1 cell line has been used previously to establish pathway
changes relevant to the calvaria. As craniosynostosis is primarily a
bone problem, bone is found where a patent joint should be, we
focused our attention to osteogenic factors, as well as biochemical
markers that have been previously associated with craniosynosto-
sis. We hypothesized exogenous exposure to thyroid hormone
would increase markers of osteogenesis in these mouse calvarial-
derived cells.
Materials and Methods
Cells
The MC3T3-E1 murine osteoprogenitor cells, harvested from
murine calvaria and purchased as a stock immortalized cell line
(American Type Culture Collection (ATCC), Manassas, VA), were
utilized in these studies on thyroxine (T4) (Sigma Aldrich, Saint
Louis, MO) exposure. Cells were reconstituted and grown in a T-
75 flask until transfer into T-175 flask. Cells were cultured in alpha
minimum Eagles medium (aMEM) supplemented with penicillin/
streptomycin (pen/strep) and 1% fetal bovine serum (FBS).
Culture
For end-point assays, proliferation (MTS) and quantitative
alkaline phosphatase (qALP), experiments were seeded in 96 well
plates at a density of 4,000 cells per well. Treatments below were
run in triplicate wells (averaged), and the studies were run in excess
of triplicates (.3 plates per experiment, per time point). To test
the effects of thyroxine hormone on mouse calvarial cells
treatments were designed as follows 1) proliferation medium:
control cells fed proliferation medium; and 2) Thyroxine
reconstituted at concentrations of 161024, 161025, 161026,
161027, 161028, 161029, 1610210 mM. Cultures were treated
for 3 or 7 days feeding every other day. Doses were chosen to
mimic slight (subclinical) elevations in thyroid levels based on
previous studies [26,27,28,29].
For RNA extractions, experiments were set up in 6 well plates
with 3 wells as control untreated cells, and 3 well thyroxine treated
cells at the dose determined effective by the above endpoint assays.
Seeding density was 50,000 cells per well. Samples in excess of
triplicates (plates = samples) were utilized for studies at each time
point. To test the effects of thyroxine hormone on biochemical
markers related to osteoegensis of mouse calvarial cells treatments
were set up as follows 1) proliferation medium: control cells fed
proliferation medium or 2) Thyroxine 161026 mM. Cultures were
treated for 3 or 7 days feeding every other day.
RNA Isolation
Cells were detached, lysates pelleted and RNA isolated using the
Qiagen, RNeasy Plus Kit (Valencia, CA) following standard
protocol. Quantity and quality of RNA was assessed using a
Spectrophotometer (Nanodrop 1000, Wilmington DE). All ratios
of absorbance at 260 and 280 nm were greater than 2.0.
Osteoprogenitor Cell Proliferation Measures
Cell proliferation was determined by Cell-titer 96 aqueous solution
cell proliferation assay kit (Promega, Madison, WI). After 3 or 7 days
of treatment, cells were incubated with 20 ul of the solution added
to each well. The absorbance was read at 490 nm and recorded
(VersaMax, Molecular Devices, Sunnyvale, CA). Percent change
in proliferation relative to baseline control measure (proliferation
media treatment only) was assessed for each treatment.
Figure 1. Proliferation: Cell proliferation assay after thyroxine
treatment. Reference line indicates control (untreated) response and
experimental group plotted as percent response compared to reference
(error bars = standard error of the mean). Note the increases in
proliferation after 3 and 7 days of treatment with the exception of
the highest dose after 7 days.
doi:10.1371/journal.pone.0069067.g001
Thyroxine Effects on Pre-Osteoblasts
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Quantitative Alkaline Phosphatase Measures
Cell differentiation was estimated using an Alkaline Phosphatase
(ALP) activity assay. ALP is an early biochemical marker for
osteoblast differentiation. After 3 or 7 days of treatment, medium
was removed from cells, and cell lysis was performed using Triton
6100 at 0.01% (Sigma Aldrich, Saint Louis, MO). After 30 min of
incubation at 4uC, deionized water and a p-Nitrophenyl
phosphate solution was added to the lysis buffer. Three control
wells containing no cells were also treated and served as blank
controls to mathematically subtract the effects of the lysis buffer
and water on final optical densities. Plates were incubated at room
temperature in the dark for 30 min. The absorbance at 405 nm
was recorded with a 96-well microplate reader. ALP activity was
Figure 2. (a) Quantitative Alkaline Phosphatase: Alkaline Phosphatase activity assay indicative of cell differentiation. Reference line
indicates control (untreated) response and experimental group plotted as percent response compared to reference (error bars = standard error of the
mean). Note the great increases in response after 7 days of treatment for doses 1025 through 1027mM. (b) Alkaline Phosphatase Stain. Representative
assay for Alkaline Phosphatase after 7 days in culture with thyroxine treatment. PM indicated proliferation media only. 24,25,26,27,28,29,10
indicated thyroxine dose doses 1024 through 10210mM.
doi:10.1371/journal.pone.0069067.g002
Table 1. Quantitative Polymerase Chain Reaction Primer Data.
Gene Symbol Gene Name Primer Sequence Reverse Primer
RUNX2 Runt Related Transcription Factor 2 Mm00501584_m1 GAGCCAGGCAGGTGCTTCAGAACTG
ALP Alkaline Phosphatase Mm00475834_m1 TGTGGCCCTCTCCAAGACATATAAC
OCN Osteocalcin Mm01741771_g1 CAGACAAGTCCCACACAGCAGCTTG
TWIST1 Twist Homolog 1 Mm00442036_m1 CAGGCCGGAGACCTAGATGTCATTG
HTRA1 HtrA serine peptidase 1 Mm00479892_m1 GGCAGAAGCCGGAGGGCTCAAGGAA
IGF1 Insulin Like Growth Factor 1 Mm00439560_m1 GCTTTTACTTCAACAAGCCCACAGG
PHEX Phosphate regulating gene with homologies to
endopeptidases on the X chromosome
Mm01166563_m1 CCACAATTTAGGGTCAATGGTGCCA
Col2a1 Collagen, Type II, alpha 1 Mm01309565_m1 GGTGACGACGGTGAAGCTGGGAAGC
TNF Tumor Necrosis Factor Mm00443260_g1 CCACGTCGTAGCAAACCACCAAGTG
FGF1 Fibroblast Growth Factor 1 Mm00438906_m1 AGCACATTCAGCTGCAGCTCAGTGC
FGF2 Fibroblast Growth Factor 2 Mm00433287_m1 AGAGCGACCCACACGTCAAACTACA
POR P450 (cytochrome) oxidoreductase Mm00435876_m1 GCAAGATCCAGACAACGGCCCCACC
DCN Decorin Mm00514535_m1 GATCCCTCAAGGTCTGCCTACTTCT
MMP9 Matrix Metallopeptidase 9 Mm00442991_m1 TCCAGTACCAAGACAAAGCCTATTT
DMP1 Dentin Matrix Protein 1 Mm01208363_m1 CTCTGAAGAGAGGACGGGTGATTTG
18S 18S ribosomal RNA Mm03928990_g1 TACTTGGATAACTGTGGTAATTCTA
doi:10.1371/journal.pone.0069067.t001
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then calculated using the following formula: ((optical density – the
mean optical density of the control wells)*total volume*dilution)/
(18.45*sample volume). Percent change in differentiation relative
to baseline control measure was assessed for each treatment.
Quantitative Polymerase Chain Reaction for Markers of
Osteoblastogenesis
Quantitative Polymerase Chain Reactions were run using a
one-step kit for cDNA synthesis and gene expression (Life
Technologies, Grand Island, NY). A master mix was made from
nuclease free water, Taqman Master Mix, RT/Rnase inhibitor
and commercially prepared probe/primer sets (Table 1). 3 ml of
RNA was added to the master mix for q-PCR for each gene
product for each condition time (3, or 7 day) by treatment (media
or levothyroxine). Expression data was normalized to 18 s
expression by DDCT. Quantitative data was compared by a time
(3 or 7 day) by treatment (media or levothyroxine) 262 analysis.
Genes of interest were Runx2, an early marker of osteogenesis, Alp,
osteocalcin (Ocn), an osteoblast specific marker, and Twist1, shown
to be important for stemness of cells and maintenance of the
undifferentiated calvarial suture [30,31].
Gene-Chip Array for Gene Expression
GeneChipH Mouse Gene 1.0 ST Array (Affymetrix, Santa
Clara, CA) was utilized to determine target gene products that
were dysregulated after 3 and 7 days of thyroxine exposure in our
cells. This technology enables whole-genome gene-level expression
studies for well-characterized genes. The GeneChip-brand array is
comprised of over 750,000 unique 25-mer oligonucleotide features
constituting over 28,000 gene-level probe sets. Initially, 150 ng of
total RNA for control and thyroxine treated cell (161026 mM)
were examined for quality and quantity by bioanalyzer analysis
(Agilent 2100, Santa Clara, CA). All sample rRNA ratios were
greater than 2.5, and RNA integrity values were greater than 8.
250 ng of RNA was then used to prepare probes per sample.
Samples were then compared by treatment (control or thyroxine)
for 3 and 7 day time points. Fold changes greater than 2, or less
than 22 are reported.
Targeted Array for Gene Expression of Genes related to
Osteogenesis
The Mouse Osteogenesis RT2 ProfilerTM PCR Array (Qiagen,
Valencia, CA) was utilized to further determine target gene
products that were dysregulated after 7 days of thyroxine exposure
in our cells. This array contains 84 genes that function in the
development of the skeletal system as well as bone mineral
metabolism. Purified RNA, 1 mG, was subjected to DNA
elimination and then reversed transcribed to cDNA using the
RT2 First Strand Kit (Qiagen,Valencia CA). The cDNA was then
mixed with the RT2 SYBR Green Mastermix, and aliquoted into
the wells of the array place. PCR was then performed (ABI 7300,
Life Technologies, Grand Island New York) using standard
protocol. Expression data between the control and thyroxine
treated samples were compared by DDCT. Fold changes greater
than 2, or less than 22 were considered significant and reported.
Quantitative Polymerase Chain Reaction Confirmation of
Array Targets
Dysregulated targets of interest resulting from the Gene-Chip
array or the targeted osteogenic array were chosen for confirma-
tion by qPCR (Table 1). Targets were chosen if they were a major
component of the bone development pathway or have been
implicated in dysregulation seen in craniosynostosis. Quantitative
PCR was performed as described above using a one-step kit.
Expression data was normalized to 18s expression by DDCT.
Quantitative data was compared by a time (3 or 7 day) by
treatment (media or levothyroxine) analysis.
Statistical Analysis
For proliferation and quantitative alkaline phosphatase, AN-
OVA was conducted for time in culture (3 or 7 day) by hormone
treatment (thyroxine hormone doses between 10ˆ-4 mol through
10ˆ-10 mol). Intergroup differences were assessed using a post-hoc
Bonferroni multiple comparison. Mean differences were consid-
ered significant if p,0.05. For arrays and qrt-PCR analysis mean
fold changes were compared with a 2 fold change (upregulated or
down regulated) being considered significant.
Figure 3. Gene Expression: Fold change mRNA for markers of
osteoblastogenesis after thyroxine treatment for 3 or 7 days
(error bars = standard error of the mean fold change). Note
greater than two-fold up-regulations (reference lines) for alkaline
phosphatase and osteocalcin.
doi:10.1371/journal.pone.0069067.g003
Figure 4. Array Confirmation: Confirmation of targets from gene
arrays of interest. Expressed as fold changes mRNA after thyroxine
treatment for 3 or 7 days (error bars = standard error of the mean fold
change). Note two-fold changes (reference lines) or greater for targets:
Phex, DMP1, HTRA1,FGF1,FGF2, POR, DCN, IGF1, and MMP9.
doi:10.1371/journal.pone.0069067.g004
Thyroxine Effects on Pre-Osteoblasts
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Results
Proliferation of Osteoprogenitor Cells is Affected by
Thyroxine Treatment
MTS assay was conducted to investigate whether thyroxine
treatment elicited changes in cell proliferation. An increase was
observed in proliferation for the 3 and 7 day thyroxine treated
assays, t = 9.818, p,0.001. To assess changes in cell proliferation
after thyroxine treatment, culture data is presented as a percent
change compared to baseline (proliferation media treated only).
For the two-way comparison of days in culture by dose, there was
no significant difference, p = ns. For days in culture there was a
significant difference, F = 49.446, p,0.001 with the 3 day data
showing a greater percent increase x= 140.30+/23.74, compared
to the cells treated for 7 days in culture, x = 115.94+/23.25
(mean+/2 standard error). For dose of thyroxine there was a
significant difference, F = 12.331, p,0.001. Post hoc Bonferroni
analysis revealed the 161024 mol dose elicited a decrease in cell
proliferation compared to baseline, p,0.05 and compared to the
other doses which elicited increased proliferation (Figure 1).
Alkaline Phosphatase is Increased after Treatment with
Thyroxine
To analyze early osteoblast differentiation, quantitative alkaline
phosphatase (ALP) analysis was performed. Thyroxine treatment
elicited a greater response for ALP compared to baseline for 3 and
7 day treated assays, t = 2.669, p= 0.009. To assess changes in
ALP after thyroxine treatment, culture data is presented as a
percent change compared to baseline (proliferation media treated
only). For the two-way comparison of days in culture by dose,
there was no significant difference, p = ns. There were no
significant differences in ALP by thyroxine dose, p = ns. There
was a significant difference for ALP by days in culture, F = 4.657,
p = 0.035, with a greater percent increase in ALP for cells treated
with thyroxine for 7 days in culture, x = 154.93+/221.75
compared to cells treated for 3 days, x = 105.88+/24.31
(mean+/2 standard error) (Figure 2a,b).
Quantitative Polymerase Chain Reaction Confirms
Increased Expression of Osteoblast Markers
Quantitative polymerase chain reaction was conducted to
determine if mRNA expression occurred after thyroxine treat-
ment. qPCR results were calculated using a DDCT methodology.
Results showed that after thyroxine treatment a greater than 2
mean fold changes resulted for expression in Alp after 3 and 7 days
of in culture and Ocn exhibiting an increase at 7 days in culture.
Runx2 and Twist1 appeared relatively stable exhibiting no
significant mean fold changes (Figure 3).
Gene-Chip Array Confirms the Specific Effect of
Thyroxine Treatment and Other Markers of
Osteoblastogenesis
Gene-Chip Affymetrix Array was conducted to determine
which genes would have expression changes after thyroxine
treatment (GEO accession GSE47517). The results of the Gene-
Chip array demonstrated 14 genes to be significantly up-regulated
(greater than 2 fold expression change) and 4 genes to be
significantly down-regulated (greater than 22 fold expression
change) after 3 days of thyroxine exposure (Table 2). For the up-
regulated genesm those of great interest to bone development or
metabolism were Htra1 which regulates the bioavailability of
Insulin like growth factors (Igfs). The array results further
demonstrated 37 genes to be significantly up-regulated (greater
than 2 fold expression change) and 11 genes to be significantly
down-regulated (less than 22 fold expression change) after 7 days
of thyroxine exposure (Table 3). For the up-regulated genes, those
of particular interest to bone development or metabolism were
several isoforms of osteocalcin (also denoted Bglap), Insulin like
growth factor (Igf1) and Por which is involved in P450 metabolism.
For the down-regulated genes, Decorin (Dcn) was of interest to
bone. Dcn acts to encode its protein which is a component of
connective tissue, binds to type I collagen fibrils, and plays a role in
matrix assembly.
Table 2. Gene-Chip MicroArray, Genes Dysregulated after 3 days of Thyroxine Treatment.
Gene Symbol Gene Name Gene Symbol Gene Name
Upregulated Downregulated
Pcolce2 procollagen C-endopeptidase enhancer 2 Pappa2 pappalysin 2
Klf9 Kruppel-like factor 9 Lrrc17 leucine rich repeat containing 17
Ret ret proto-oncogene Zcchc5 zinc finger, CCHC domain containing 5
Slc27a1 solute carrier family 27 (fatty acid transporter), member 1 Igsf10 immunoglobulin superfamily, member 10
Htra1 HtrA serine peptidase 1
Smpdl3b sphingomyelin phosphodiesterase, acid-like 3B
Spon2 spondin 2, extracellular matrix protein
Tmod1 tropomodulin 1
Igfbp4 insulin-like growth factor binding protein 4
Zscan4a zinc finger and SCAN domain containing 4
Slc40a1 solute carrier family 40 (iron-regulated transporter), member 1
Mir181b-1 microRNA 181b-1
Gtf3c2 general transcription factor IIIC, polypeptide 2
Fam43a family with sequence similarity 43, member A
doi:10.1371/journal.pone.0069067.t002
Thyroxine Effects on Pre-Osteoblasts
PLOS ONE | www.plosone.org 5 July 2013 | Volume 8 | Issue 7 | e69067
Targeted Osteogenic Array Confirms Positive Effect of
Thyroxine on Osteoblastogenesis
A targeted osteogenic array was also conducted to further
determine if genes associated with osteogenesis had expression
changes after treatment with thyroxine. The results of the targeted
osteogenic array after 7 days of thyroxine exposure demonstrated
22 gene products as up-regulated and 1 gene product was
identified as down-regulated (Table 4). The remaining gene
products were found to have fold change of ,2 and .22, with no
significant mean fold changes.
Confirmation of Dysregulated Array Targets
Of the targets identified by microarray, 11 gene products were
chosen for qPCR confirmation. The gene products chosen were of
particular interest to craniofacial bone development or craniosyn-
ostosis and were: Phex, Col2a1, Tnf, Dmp1, Htra1, Fgf1, Fgf2, Por,
Table 3. Gene-Chip MicroArray, Genes Dysregulated after 7 days of Thyroxine Treatment.
Gene Symbol Gene Name Gene Symbol Gene Name
Upregulated Downregulated
Bglap2 bone gamma-carboxyglutamate (gla) protein Lum lumican
Tmod1 tropomodulin 1 Zcchc5 zinc finger, CCHC domain containing 5
Smpdl3b sphingomyelin phosphodiesterase, acid-like 3B Lrrc17 leucine rich repeat containing 17
Pfkfb3 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3
ND6 mitochondrially encoded NADH dehydrogenase 6
Pcolce2 procollagen C-endopeptidase enhancer 2 AY036118 cDNA
Klf9 Kruppel-like factor 9 Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2
Bdkrb1 bradykinin receptor B1 Snora73b small nucleolar RNA, H/ACA box 73B
Tgtp1 T cell specific GTPase 1 Efhd1 EF-hand domain family, member D1
Htra1 HtrA serine peptidase 1 Fut11 fucosyltransferase 11 (alpha (1,3) fucosyltransferase)
9930013L23Rik RIKEN cDNA 9930013L23 gene Dcn Decorin
Fam180a family with sequence similarity 180, member A Robo2 roundabout, axon guidance receptor, homolog 2
(Drosophila)
Spon2 spondin 2, extracellular matrix protein
Ccl5 chemokine (C-C motif) ligand 5
Ret ret proto-oncogene
Igf1 insulin-like growth factor 1 (somatomedin C)
Npr3 natriuretic peptide receptor C/guanylate cyclase C
Mir181b-1 microRNA 181b-1
Bglap-rs1 bone gamma-carboxyglutamate (gla) protein
Por P450 (cytochrome) oxidoreductase
Slc40a1 solute carrier family 40 (iron-regulated transporter),
member 1
Slc43a2 solute carrier family 43, member 2
Trp53inp2 tumor protein p53 inducible nuclear protein 2
A930018M24Rik RIKEN cDNA A930018M24 gene
Heg1 HEG homolog 1 (zebrafish)
Fam43a family with sequence similarity 43, member A
9930111J21Rik2 RIKEN cDNA 9930111J21 gene
Heg1 HEG homolog 1 (zebrafish)
Ampd3 adenosine monophosphate deaminase 3
Fam20c family with sequence similarity 20, member C
Sned1 sushi, nidogen and EGF-like domains 1
Trdn triadin
Olfr767 olfactory receptor 767
9930111J21Rik2 RIKEN cDNA 9930111J21Rik2
Olfm2 olfactomedin 2
Slc27a1 solute carrier family 27 (fatty acid transporter),
member 1
Adrb2 adrenergic, beta-2-, receptor, surface
Itgbl1 integrin, beta-like 1 (with EGF-like repeat domains)
doi:10.1371/journal.pone.0069067.t003
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Dcn, Igf1 andMmp9. Results suggest significant dysregulations for 9
of these gene products after 3 or 7 days of thyroxine exposure
(Figure 4).
Discussion
It appears thyroid hormone may exert its effects on calvarial
cells through increasing osteogenesis. Our data suggests an
increase in proliferation at our early time point, and a bell-like
curve response with our lowest and highest doses of thyroxine
showing little effect typical of hormonal effects on cells. For
alkaline phosphatase activity we observe an increase after 7 days
in culture. These data are consistent with early increase in
proliferation and later increase in differentiation suggesting that
osteogenesis may be increased in these cells after exogenous
thyroxine exposure. This relationship was confirmed with
quantitative PCR which showed an increase in Alp expression at
3 and 7 days in culture and an increase in Ocn expression after
7 days in culture exposed to exogenous thyroxine. Runx2 was not
observed to be up-regulated. We would expect to see Runx2
upregulation in cells destined to become osteoblasts as it is one of
the earliest and an essential markers for osteoblasts. It may be that
an earlier time point (perhaps 24 or 48 hours) would be necessary
to capture its up-regulation.
Our genome wide array analysis identified 18 genes with
significant changes in regulation after 3 days of exposure to
thyroxine and 48 genes after 7 days of exposure to thyroxine.
Although many genes were of interest, we selected genes to
confirm by quantitative PCR in a greater sample (n = 3 for 3 days,
and n= 3 for 7 days in culture) due to their relevance to bone and
craniofacial biology. Among these genes were Htra1 which was
significantly up-regulated after 3 and 7 days in culture with
thyroxine. This could have been predicted as HTRA1 is thought
to regulate the availability of Insulin Like Growth Factor (IGF)
[32]. Thyroid hormone has a positive effect on bone and bone cell
growth through the IGF pathway [33,34]. In addition, Igf1 was
significantly up-regulated after 7 days in culture exposed to
thyroxine. In vivo, IGF1 is a mediator for the effects of growth
hormone as well as a growth promoter for all cells in the body. An
increase in the expression of Igf would translate to an increase in
target cell proliferation and differentiation. Both of these genes
were further confirmed by q-PCR to be significantly up-regulated
at both 3 and 7 days in culture.
Two other genes from our genome wide array that showed
significant dysregulation at 7 days were of interest. P450 reductase
or Por is a membrane bound enzyme necessary for electron
transfer in cell, from NADP to cytochrome P450 in microsomes
[35]. Deficiency in POR has been linked to various diseases
including disorders of steroidogenesis and Antley Bixler cranio-
synostosis syndrome [36]. However, we observed an upregulation
in expression which may be suggestive of merely greater cell
activity (proliferation/differentiation). Perhaps this is another
example of a gene that required tight homeostasis to allow for
normal growth and development of the calvaria. We further
Table 4. Targeted Osteogenic MicroArray, Genes Dysregulated after Thyroxine Treatment.
Gene Symbol Gene name
Upregulated
Alpl Alkaline phosphatase, liver/bone/kidney
Bmpr1b Bone morphogenetic protein receptor, type 1B
Col10a1 Collagen, type X, alpha 1
Col11a1 Collagen, type XI, alpha 1
Col14a1 Collagen, type XIV, alpha 1
Col7a1 Collagen, type VII, alpha 1
Csf2 Colony stimulating factor 2 (granulocyte-macrophage)
Csf3 Colony stimulating factor 3 (granulocyte)
Dmp1 Dentin matrix protein 1
Fgf1 Fibroblast growth factor 1
Fgf2 Fibroblast growth factor 2
Fgf3 Fibroblast growth factor 3
Gdf10 Growth differentiation factor 10
Icam1 Intercellular adhesion molecule 1
Igf1 Insulin-like growth factor 1
Itga2 Integrin alpha 2
Mmp8 Matrix metallopeptidase 8
Mmp9 Matrix metallopeptidase 9
Phex Phosphate regulating gene with homologies to endopeptidases on the X chromosome (hypophosphatemia, vitamin D resistant rickets)
Tnf Tumor necrosis factor
Vdr Vitamin D receptor
Vegfa Vascular endothelial growth factor A
Downregulated
Col2a1 Collagen, type II, alpha 1
doi:10.1371/journal.pone.0069067.t004
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confirmed significant upregulation of Por at both 3 and 7 days in
culture with thyroxine exposure.
Decorin codes for a small cellular proteoglycan which is part of
connective tissue binding to type I collagen fibrils and playing a
role in extracellular matrix assembly. Decorin is thought to
regulate Transforming growth factor beta (TGFB) bioavailability
and mutations in this gene have been linked to Marfan syndrome
[37,38]. Decorin has also been identified at the cranial suture with
importance for suture formation and growth linked to its
expression [39]. In addition, a study investigating the effects of
FGF2 administration to Crouzon Syndrome (FGFr Autosomal
Dominant Craniosynostosis Syndrome) patient derived parietal
bone osteoblasts suggested an inverse relationship between FGF2
and DCN [40]. Overexpression of FGF2 has been implicated in
craniosynostosis. We confirmed Dcn to be significantly down-
regulated after 7 days in culture with thyroxine and as discussed
below an upregulation of FGF2.
Our targeted osteoblast bone microarray after 7 days in culture
identified 23 genes that were significantly dysregulated, 22 up-
regulated and 1 down-regulated. Igf1 was significantly up-
regulated in our array and was confirmed as up-regulated. From
these targets we chose to confirm 7 by qPCR, Phex, Col2a1, Tnf,
Dmp1, Fgf1, Fgf2, and Mmp9. Dysregulation of Col2a1 and Tnf was
not confirmed. There are many reasons why a significant value
could be obtained from a microarray analysis that is not confirmed
by quantitative PCR, or vice versa including threshold reliability,
fold change, intensity, and basic variability [41]. Tnf or Tumor
necrosis factor was slightly up-regulated after 7 days in culture.
This gene is important in apoptosis, mediates osteoclastogenesis
and may have an inverse relationship with TWIST, with TWIST
decreasing TNF mediated osteoclastogenesis [42,43]. The slight
upregulation seen here is most likely due to an increase in
apoptosis of our cells. Col2a1showed a slight downregulation at
both 3 and 7 days in culture. This gene allows for the production
of type II collagen which provides structure and strength to
connective tissues of bone, muscles, joints, and organs. Type II
collagen is found primarily in cartilage [44,45]. Chondrogenesis
normally involves an increase in the expression of Col2a1 and a
decrease in Col1a1. Thus, this down-regulation of Col2a1 may be
an effect of promoting intramembranous ossification.
We did confirm increased expression in the genes Phex, Dmp1,
Fgf1, Fgf2 and Mmp9. PHEX is important in bone mineralization
and deficiencies are linked to Vitamin D deficient rickets. It has
been observed that Phex shows increased expression in osteoblasts
especially during the transition from pre-osteoblasts to mature
osteoblasts [46]. MMP9 or matrix metallopeptidase 9 is involved
in the breakdown of extracellular matrix. MMP9 has been
associated with differentiated osteoblasts in bone and the cranial
suture. MMP9 is also a marker of osteoclast activity and
remodeling [47]. DMP1 or Dentin matrix acid phosphoprotein
is an ECM protein which is necessary for proper mineralization of
bone. It regulates the expression of osteoblast specific genes and
during osteoblast maturation the protein is phosphorylated and
exported to the ECM where it orchestrates mineralized matrix
formation [48]. In addition, in a mouse model that overexpressed
DMP1, enhanced mineralization was shown at the cranial sutures
[49]. Thus, the up-regulation of Dmp1 at 7 days may be a target
for future studies investigating molecular expression in suture
fusion due to thyroid hormone exposure.
The fibroblast growth factors (FGFs) are a family of growth
factors involved in angiogenesis, wound healing and development
[31,50,51]. The fibroblast growth factor receptors have been
implicated in syndromic and non-syndromic forms of craniosyn-
ostosis [52,53,54,55]. We observed an upregulation in Fgf1,2 and 3
after 7 days in culture in our targeted microarray. We were further
able to confirm a significant upregulation for both Fgf1 and Fgf2
after 7 days in culture with thyroxine treatment. Both FGF1 and 2
have been shown to allow for growth of fetal and neonatal
osteoblasts, and FGF2 is critical for calvarial development
[50,52,53,56,57]. An upregulation in Fgf2 can be indicative of
osteoblast differentiation and had been linked to greater expression
of downstream osteoblast targets, i.e. osteocalcin. FGF2 also aids
in the control of the amount of apoptosis that occurs at the
calvarial suture and the balance between undifferentiated and
differentiated cells in the suture by promoting differentiation and
apoptosis of more mature osteoblasts [50,52,56,57,58,59]. FGFs
may play a role in regulating IGF’s effect on growth of calvarial
cells, and in concert with TGFB1, FGF2 has been shown to be up-
regulated in cranial sutures that are fusing [25,45]. These up-
regulated targets are also potential objectives for future studies
investigating molecular expression in suture fusion due to thyroid
hormone exposure.
Concerning translation to craniofacial biology our data speak to
a specific relationship between calvarial cells and excess thyroid
hormone exposure. We confirmed increases in markers of
osteogenesis including Alp, Ocn, and Mmp9. We also confirmed
targets that should be up-regulated in the presence of thyroid
hormone, Htra1 and Igf1, suggesting these cells are susceptible to
thyroid hormone stimulation. In addition, the constituent decrease
in Dcn and increase in Fgf2 as well as Fgf1 present possible targets
in the pathway of effect for thyroxine exposure and osteogenesis of
the calvarial cells, and perhaps suture. Overall, our targets suggest
a possible interaction for those gene products associated with
calvarial suture growth and homeostasis as well as craniosynosto-
sis.
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